STOCK PICK OF THE DAY

Repros Therapeutics Inc (NASDAQ: RPRX)  

•  
•  
•  
• 

5.04  +0.86 +20.57%

MORE ON RPRX

• SUMMARY
• Quote
• Options
• Historical Prices
• CHARTS
• Interactive Chart
• NEWS
• Headlines
• Key Developments
• FUNDAMENTALS
• Financial Highlights
• Profile
• Key Ratios
• 10-Year Summary
• Earnings
• SEC Filings
• RATINGS/ANALYSIS
• StockScouter Report
• Analyst Ratings
• INSIDER ACTION
• Insider Trades
• Ownership
• FINANCIALS
• Income Statement
• Balance Sheet
• Cash Flow
•  

COMPANY ADDRESS

Repros Therapeutics Inc
SUITE B-7, 2408 TIMBERLOCH PL
THE WOODLANDS, TX 77380
US - Map
Phone: 281-7193400
Fax: 281-7193446
Website 

COMPANY INFORMATION

Exchange:	NASDAQ
Stock:	Repros Therapeutics Inc.
Industry:	Biotechnology
Employees:	13

DESCRIPTION

Repros Therapeutics Inc. (Repros) is a development stage biopharmaceutical company. It is focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidate include Androxal and Proellex. Androxal, is a single isomer of clomiphene citrate and is an orally active small molecule compound. It is developing Androxal for men of reproductive age with low testosterone levels. Androxal treats the underlying mechanism that causes secondary hypogonadism and restores normal testicular function. As of December 31, 2010, Repros was conducting a Phase 2 clinical trial of Androxal as a potential treatment for Type 2 diabetes. Proellex, an orally administered selective blocker of the progesterone receptor in women , for the treatment of uterine fibroids and endometriosis.